Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CorMedix Inc. CRMD
$5.21
-$0.1 (-1.88%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
242523910.00000000
-
week52high
8.03
-
week52low
2.65
-
Revenue
65408
-
P/E TTM
-7
-
Beta
2.14463600
-
EPS
-0.73000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 12 авг 2022 г. |
| Needham | Buy | Buy | 09 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 09 авг 2022 г. |
| Needham | Buy | Buy | 14 мая 2021 г. |
| Needham | Buy | 17 февр 2021 г. | |
| Needham | Buy | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mistry Erin | A | 75000 | 75000 | 14 янв 2023 г. |
| Mounts Phoebe | A | 125000 | 125000 | 14 янв 2023 г. |
| Todisco Joseph | A | 400000 | 400000 | 14 янв 2023 г. |
| Lefkowitz Steven W | A | 20000 | 20000 | 14 янв 2023 г. |
| Masson-Hurlburt Elizabeth | A | 125000 | 125000 | 14 янв 2023 г. |
| Kaplan Myron | A | 20000 | 20000 | 14 янв 2023 г. |
| Dillione Janet | A | 20000 | 20000 | 14 янв 2023 г. |
| DUNTON ALAN W | A | 20000 | 20000 | 14 янв 2023 г. |
| David Matthew T | A | 125000 | 125000 | 14 янв 2023 г. |
| Duncan Gregory Scott | A | 20000 | 20000 | 14 янв 2023 г. |
Новостная лента
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
03 мая 2023 г. в 08:30
BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 15 – 16, 2023 and the 2023 RBC Capital Markets Global Healthcare Conference being held in New York on May 16 – 17, 2023. Details for each fireside chat is as follows:
7 Small-Cap Biotech Stocks with Massive Potential
InvestorPlace
27 апр 2023 г. в 18:36
While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
Zacks Investment Research
27 апр 2023 г. в 11:27
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023
GlobeNewsWire
21 мар 2023 г. в 08:30
BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2022, before the market opens on Thursday, March 30, 2023, and will host a corporate update conference call at 8:30am Eastern Time.
5 Penny Stocks To Buy According To Analysts, Targets Up To 353%
PennyStocks
11 ноя 2022 г. в 10:38
Analysts say these are penny stocks to buy. Do you agree?